Objective-The association between insulin resistance (IR) and coronary artery calcification (CAC) has been uncertain after adjustment for metabolic syndrome components. We aimed to evaluate whether IR is associated with CAC prevalence or progression independently of metabolic syndrome components. Approach and Results-We conducted a population-based study in a random sample of Japanese men aged 40 to 79 years and determined IR using the homeostasis model assessment of insulin resistance (HOMA-IR). The associations of HOMA-IR and other diabetic parameters per 1-SD increase with CAC prevalence and progression were evaluated using multivariable logistic regression. Of 1006 total participants at baseline (mean age, 64±10 years), CAC prevalence was observed in 646 (64.2%), and of 789 participants at follow-up (mean duration, 4.9±1.3 years), CAC progression was observed in 365 (46.3%). After adjustment for covariates including metabolic syndrome components, higher HOMA-IR was independently associated with CAC prevalence (adjusted odds ratio 1.34, 95% confidence interval 1.10-1.63; P=0.003) and progression (odds ratio 1.32, 95% confidence interval 1.09-1.60; P=0.004). In participants without diabetes mellitus, positive associations were similarly observed (prevalence: odds ratio 1.29, 95% confidence interval 1.04-1.60; P=0.022; and progression: odds ratio 1.25, 95% confidence interval 1.01-1.55; P=0.042), whereas glucose and hemoglobin A1c were not associated with CAC prevalence and progression. Conclusions-Higher IR was associated with CAC prevalence and progression independently of metabolic syndrome components in Japanese men and also in those without diabetes mellitus. Among diabetic measures, IR and fasting insulin, but not glucose and hemoglobin A1c, predicted CAC progression in men without diabetes mellitus. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
C ardiovascular diseases, particularly coronary heart disease (CHD), are the one of the leading causes of death worldwide. The risk of CHD is 2× greater in patients with type 2 diabetes mellitus than in those free of the disease. 1 Before diabetes mellitus is diagnosed, insulin resistance (IR) can be present for years, thereby increasing insulin and glucose concentrations, which can promote atherosclerosis. 2, 3 The World Health Organization has also emphasized IR as a major underlying risk factor of metabolic syndrome (MetS). 4 However, in several earlier reports, the association between IR and prevalence of coronary artery calcification (CAC), a surrogate marker of subclinical atherosclerosis, has been inconsistent after adjustment for metabolic factors, such as hypertension, dyslipidemia, and body mass index. [5] [6] [7] Moreover, progression of CAC has been reported to be associated with future CHD events, 8 whereas the relation of IR to progression of CAC has remained unclear. 9 Studies that focused on populations with a lower risk of CHD events, such as Asian populations, have also been scarce. 10 August 2016
In recent basic science reports, IR could promote atherosclerosis not only through mechanisms that involve systemic factors, such as dyslipidemia, hypertension, and a proinflammatory state, but also through the effect of perturbed insulin signaling at the level of the intimal cells. 11, 12 The purpose of this study was to evaluate whether IR is independently associated with CAC prevalence or CAC progression in consideration of MetS components in a general Japanese population, and particularly in those without diabetes mellitus.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

CAC Prevalence
The baseline characteristics of all participants according to CAC prevalence are shown in Table 1 and those of nondiabetic participants are shown in Table I in the onlineonly Data Supplement. We found CAC prevalence of 646 (64.2%) in total participants and in 479 (60.2%) in nondiabetic participants. The participants with CAC prevalence were older and had more pack-years of smoking, higher systolic and diastolic blood pressure and triglyceride levels, and a lower high-density lipoprotein cholesterol levels compared with those without CAC prevalence. Regarding the diabetic parameters, we found statistically significant differences in fasting glucose, hemoglobin A1c (HbA1c), fasting insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) between participants with and without CAC prevalence. Medication use for hypertension, dyslipidemia, and diabetes mellitus were also more frequent in participants with CAC prevalence. Obesity parameters, such as body mass index and waist circumference, were higher in the CAC prevalence group. Table 2 shows the results of multivariable logistic regression for the association between diabetic parameters and CAC prevalence in total and nondiabetic participants. In all participants, any diabetic parameters were significantly associated with CAC prevalence (model 1 and 2). However, the odds ratios (ORs) of CAC prevalence were higher for 1-SD increases in fasting insulin and HOMA-IR compared with those for 1-SD increases in fasting glucose and HbA1c. Moreover, in nondiabetic participants, only fasting insulin and HOMA-IR were associated with CAC prevalence (model 1), and these associations (fasting insulin: OR 1.31, 95% confidence interval [CI] 1.05-1.63; HOMA-IR: OR 1.29, 95% CI 1.04-1.60) were not attenuated after adjustment for MetS components (model 2). When waist circumference was adjusted instead of body mass index (model 2), these relationships also remained. Also, when CAC prevalence at baseline was defined as baseline CAC score >10, the trend of these positive associations was still observed (data not shown).
CAC Progression
Participant characteristics according to CAC progression are described in Table II in the online-only Data Supplement. Mean follow-up duration overall was 4.9±1.3 years. We observed CAC progression in 365 (46.3%) of total participants and in 268 participants (42.7%) of nondiabetic participants. There were significant differences in all diabetic parameters, including fasting insulin and HOMA-IR, between participants with and without CAC progression. Baseline CAC score in participants with CAC progression was statistically higher compared with those without CAC progression. Table 3 shows that any measures of diabetes mellitus, including fasting insulin and HOMA-IR, were related to CAC progression independently of established risk factors in all participants (model 2). Similar to CAC prevalence, the ORs of CAC progression were higher for 1-SD increase in HOMA-IR (OR 1.32, 95% CI 1.09-1.60) compared with those for 1-SD increase in fasting glucose and HbA1c. In nondiabetic participants, fasting insulin and HOMA-IR were independently associated with CAC progression even after adjustment for MetS components (OR 1.27, 95% CI 1.01-1.55; and OR 1.25, 95% CI 1.05-1.55, respectively), whereas fasting glucose and HbA1c were not associated with CAC progression. Risk ratios for evaluating the association of diabetic measures with CAC prevalence and progression by modified Poisson regression analysis are shown in Tables III and IV in the online-only Data Supplement. As with the logistic models, the relationships of HOMA-IR and fasting insulin to CAC prevalence and progression were statistically significant.
Discussions
The present study showed that IR measured by HOMA-IR was independently associated with both CAC prevalence and CAC progression beyond the MetS components in a general Japanese male population. Of note, only fasting insulin and IR among diabetic measures were associated with CAC prevalence and predicted CAC progression in nondiabetic participants.
We found that IR was independently associated with CAC prevalence even after adjustment for MetS components. Previous studies discussed that the association of IR with CAC prevalence was attenuated after adjustment for MetS components, such as hypertension, dyslipidemia, and obesity. 6, 7 They argued that IR lies upstream of MetS and its consequences on the causal pathway for cardiovascular disease. Indeed, other investigators have indicated that people with higher fasting insulin have more severe CHD risk factors, such as hypertension and dyslipidemia. 13, 14 These studies have suggested that IR worsens CHD by exacerbating traditional CHD risk factors, that is, the MetS components. However, recent reports have showed that IR can promote atherosclerosis through the effect of perturbed insulin signaling at the level of intimal cells apart from systemic factors, such as hypertension and dyslipidemia. 11, 15 Rask-Madsen et al 16 discussed that 3 cell types, endothelial cells, vascular smooth muscle cells, and macrophages, have insulin receptors and insulin receptor-mediated signaling pathways which are downregulated markedly in the setting of hyperinsulinemia. This mechanism is responsible for the impairment in insulin-stimulated glucose metabolism and contributes to the accelerated rate of atherosclerosis. These data support the present results, and we confirm that hyperinsulinemia and IR could develop coronary atherosclerosis through a pathway independent of MetS components in a general population including nondiabetic people. The present study indicated that IR is an independent predictor of CAC progression in both overall and nondiabetic men. CAC progression has been reported to be associated with future CHD events 8 and to add incremental value in predicting all-cause mortality 17 ; thus, we should pay attention to factors associated with CAC progression. Prior studies reported that traditional cardiovascular risk factors, such as age, dyslipidemia, hypertension, body mass index, and diabetes mellitus, were independently associated with increases in CAC over time. [18] [19] [20] As far as we know, only one previous study is available that discusses the association between IR and CAC progression in a prospective community-based cohort study. 9 In that report, CAC was measured at enrollment and after 2 years in 869 healthy adults aged 60 to 72 years, including those with overt diabetes mellitus, and found that insulin but not HOMA-IR was associated with CAC progression. In our study, the wider age range of the participants (40-79 years), longer interval between computed tomographic scans (mean follow-up of 4.9±1.3 years), and confirmation of the independent association of fasting insulin and HOMA-IR with CAC progression especially in nondiabetic people overcome some limitations of the previous study.
One previous meta-analysis described that the relative risk of CHD per 1-SD increase in HOMA-IR was higher than that in fasting insulin concentration. 21 However, this report compared insulin and HOMA-IR derived from different cohort studies and nested case-control studies, and therefore, we could not directly evaluate the magnitude of the association. In fact, fasting insulin and HOMA-IR were strongly correlated (r=0.96 in total participants and r=0.98 in participants without diabetes mellitus) in our single-race general population. Further studies are needed to fully compare the strength of the association of fasting insulin and HOMA-IR with coronary atherosclerosis in other populations. IR probably has additive value to predict CAC progression in participants without diabetes mellitus. In the present study, unlike fasting insulin and IR, fasting glucose and HbA1c, which are usual clinical diabetes mellitus measures, were not associated with CAC prevalence and CAC progression, especially in nondiabetic men. In a previous study, the association between higher HbA1c and CAC prevalence was evident only in women but not in all participants. 22 Moreover, Carson et al 23 reported that higher HbA1c was independently associated only with advanced CAC progression (increase >100 Agatston units) after adjustment for cardiovascular risk factors among individuals without diabetes mellitus. These data suggest that physicians might miss and underestimate the possibility of CAC progression in nondiabetic populations, using only fasting glucose and HbA1c as measures for diabetes mellitus.
Two possible mechanisms may account for the reason why IR and fasting insulin predicted CAC progression, whereas fasting glucose and HbA1c did not. One plausible explanation would be that IR is present at the stage of impaired glucose tolerance and even before any abnormality in glucose tolerance is observed. 2 Another potential plausible explanation is the distinguished effect of IR and hyperglycemia on atherosclerosis processes reported in in vivo studies. 11, 16 IR may play important roles not only in atherogenesis but also in advanced plaque progression through promoting apoptosis of endothelial cells, macrophages, and vascular smooth muscle cells. On the contrary, hyperglycemia seems to primarily accelerate *Prevalence of baseline CAC was defined as baseline CAC score >0. †Odds ratios were for 1-standard deviation increase in continuous parameters. Model 1: each odds ratio was adjusted for age, smoking (current smoker, past smoker vs never smoker), alcohol (ethanol consumption per week), LDL cholesterol, and type of computed tomography. Model 2: adjusted for variables in model 1 plus hypertension (systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg or use of antihypertensive medication), and dyslipidemia (HDL cholesterol <40 mg/dL or triglyceride ≥150 mg/dL), use of antilipid medication, and body mass index. *Progression of CAC was defined as follows, for those with CAC=0 at baseline, defined as CAC score >0 at follow-up; for participants with 0<CAC<100 at baseline, defined as annualized change of ≥10 Agatston units at follow-up; for participants with CAC ≥100 at baseline, defined as annualized percent change (annualized change in CAC score divided by the baseline CAC score) ≥10% at follow-up. †Odds ratios were for 1-standard deviation increase in continuous parameters. Model 1: each odds ratio was adjusted for age, smoking (current smoker, past smoker vs never smoker), alcohol (ethanol consumption per week), LDL cholesterol, and type of computed tomography. Model 2: adjusted for variables in model 1 plus hypertension (systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg or use of antihypertensive medication), dyslipidemia (HDL cholesterol <40 mg/dL or triglyceride ≥150 mg/dL), use of antilipid medication, and body mass index.
formation of early and mid-stage lesions of atherosclerosis by promoting adhesion molecule expression in endothelial cells. Further basic and clinical studies are needed to confirm these possible mechanisms.
Our study has several limitations. First, currently there is no established definition of CAC progression. In addition, a considerable amount of nonbiological interscan variability may exist in the measurement of CAC because of technical factors in computed tomography. Second, the different baseline characteristics were observed between the group with CAC prevalence or progression and that without either condition. Although we have statistically adjusted for potentially cofounding factors in our multivariable regression, we recognize that the adjustment may not be able to entirely remove the confounding. Third, participants without follow-up had higher levels of systolic blood pressure and baseline CAC scores compared with those with follow-up (Table V in the onlineonly Data Supplement). There were no significant differences among the diabetic measures between the groups. Although not known for certain, participants without follow-up could have been at higher risk for CAC progression (because of a higher baseline CAC). In addition, we may have actually underestimated the association of HOMA-IR and CAC progression simply because those who were lost to follow-up reduce the sample size that should have been available in these higher-risk strata. Fourth, the study population was restricted to men of a single ethnic group; thus, our results should not be generalized to women or other races or patient populations. By contrast, this could lead to study strength because population homogeneity reduces possible confounding from genetic variation.
In summary, higher IR and fasting insulin were associated with CAC prevalence and progression independently of MetS components in Japanese men and in those without diabetes mellitus. Among diabetic measures, IR and fasting insulin, but not glucose and HbA1c, predicted CAC progression in men without diabetes mellitus.
